A plan to give people in the United States easier access to unproven peptide drugs favored by the US health secretary, Robert F Kennedy Jr, was opposed by most Food and Drug Administration scientific staff members, who had limited input in drafting the policy, according to six people familiar with its development.
uncertain
who → give → development
The document posted online on Wednesday by Kennedy’s Department of Health and Human Services (HHS) covers a handful of injectable peptides promoted within the wellness industry for building muscle, healing injuries and boosting energy.
asserted
document → post → energy
The effort on peptides, driven almost entirely by HHS, faced overwhelming pushback among FDA drug staffers who warned it could undermine the agency’s longstanding mission of keeping unproven health products off the US market, according to the people familiar with its development.
uncertain
it → drive → development
The people spoke to the Associated Press on the condition of anonymity to discuss confidential government deliberations.
asserted
people → speak → deliberations
An HHS spokesperson did not immediately respond to a request for comment.
asserted
spokesperson → respond → comment
The policy directs the FDA not to take action against specialty pharmacies that sell a half-dozen wellness peptides, including BPC-157, TB-500 and KPV.
asserted
that → direct → BPC-157
Under FDA rules, those chemicals would otherwise be considered illegal drugs because they have not gone through the agency’s rigorous review process for safety and effectiveness.
asserted
they → consider → safety
Some peptides occur naturally in the human body, where they trigger hormones needed for growth, metabolism and healing.
asserted
they → occur → growth
Drug companies have brought several to market as medications, including mainstay treatments for diabetes and weight loss.
asserted
companies → bring → diabetes
But the chemicals subject to the new policy haven’t been approved as safe and effective by the FDA.
asserted
chemicals → approve → FDA
Kennedy has called himself a “big fan” of peptides and recently described using BPC-157 to treat a muscle injury.
asserted
Kennedy → call → injury
The new document represents a step back from HHS’s original plans, according to two of the people who discussed its development.
uncertain
who → represent → development
HHS officials initially wanted the FDA to draft an official regulation that would add BPC-157 and other peptides to a list of drug substances deemed safe for use by compounding pharmacies, specialty businesses that make customized medications.
asserted
that → want → medications
FDA officials warned that the agency’s scientific staffers had major safety concerns and would not support a regulation deeming them safe.
asserted
them → warn → regulation
HHS officials moved to a different approach that directs the FDA not to enforce its rules against pharmacies that compound the substances.
asserted
that → move → substances
FDA staffers ultimately provided technical assistance in drafting the HHS plan, including guardrails intended to improve safety, such as requiring pharmacies to use peptide ingredients from FDA-registered factories.
asserted
staffers → provide → factories
Decisions over compounding have long rested with the FDA, not HHS.
asserted
Decisions → rest → FDA
Kennedy has said that US compounding pharmacies must be allowed to sell peptides because Americans are turning to “gray market” products imported from China and other countries.
asserted
Americans → say → China
Decisions about regulating peptides and compounding pharmacies have almost always come from the FDA, which has an office dedicated to protecting US consumers from unsafe or poor-quality compounded drugs.
asserted
which → regulate → drugs
The issue of compounding safety became a greater focus for the FDA after a deadly outbreak of fungal meningitis in 2012 was linked to contaminated injections from a Massachusetts compounding pharmacy.
asserted
outbreak → become → pharmacy
Once a niche business, compounding has grown into a multibillion-dollar industry, providing customized medications to doctors, clinics and hospitals.
asserted
compounding → grow → doctors
It’s extremely rare for HHS to take the lead in drafting policies over the compounding industry, former FDA officials said.
asserted
officials → ’ → industry
However, federal law technically gives HHS authority over essentially all drug regulations, which are then delegated to the FDA.
asserted
which → give → FDA
The FDA has warned Americans about safety risks of unproven peptides
Many in the US who are using peptides today do not deal with a doctor or a pharmacy to get the injections, but often order vials online sold by chemical manufacturers based in China.
asserted
who → warn → China
Peptide sellers often try to skirt US regulations by labeling their products as “for research use only” because the FDA does not regulate research chemicals.
asserted
FDA → try → chemicals
In 2023, the FDA added more than a dozen peptides, including BPC-157 and TB-500, to its list of substances that should not be compounded due to risks of allergic reactions, kidney damage and tumor growth.
asserted
that → add → reactions
At a meeting in July, FDA staffers reiterated that more than half a dozen peptides brought forward for reconsideration remained unproven in terms of safety and effectiveness.
asserted
peptides → reiterate → safety
The new policy from HHS avoids a direct confrontation with FDA staffers because it only directs the FDA not to enforce certain rules.
asserted
it → avoid → rules
HHS ultimately included several safety measures suggested by FDA staffers, according to two of the people.
uncertain
HHS → include → people
Besides sourcing ingredients from FDA-registered facilities, compounders will be directed to collect information on side effects for safety analysis and verify the chemical identity of peptides.
asserted
compounders → source → peptides
The Aporia
